Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Keefe

Showing results (231-240 of 255) with videos related to

Pageof 26
Sort By:
Journal of Affective Disorders|July 19, 2023
Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS studySabrina M Darrow, Diego A Pizzagalli, Moria Smoski, et al.
Biological Psychiatry|September 1, 2004
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteriaMichael F Green, Keith H Nuechterlein, James M Gold, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 3, 2009
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaChristine E Marx, Richard S E Keefe, Robert W Buchanan, et al.
The Journal of Clinical Psychiatry|June 13, 2012
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trialRichard S E Keefe, Sophia Vinogradov, Alice Medalia, et al.
Schizophrenia Research|March 25, 2023
Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disordersLusi Zhang, Paulo Lizano, Yanxun Xu, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 15, 2025
Beyond symptom improvement: transdiagnostic and disorder-specific ways to assess functional and quality of life outcomes across mental disorders in adultsChristoph U Correll, Samuele Cortese, Marco Solmi, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 10, 2021
Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disordersLusi Zhang, Scot Kristian Hill, Bin Guo, et al.
Archives of General Psychiatry|June 10, 2010
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosisLarry J Seidman, Anthony J Giuliano, Eric C Meyer, et al.
Archives of General Psychiatry|June 6, 2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialRichard S E Keefe, Robert M Bilder, Sonia M Davis, et al.
Nature Medicine|April 2, 2020
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedoniaAndrew D Krystal, Diego A Pizzagalli, Moria Smoski, et al.
Pageof 26

Showing results (231-240 of 255) with videos related to

Sort By:
Pageof 26
Journal of Affective Disorders|July 19, 2023
Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS studySabrina M Darrow, Diego A Pizzagalli, Moria Smoski, et al.
Biological Psychiatry|September 1, 2004
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteriaMichael F Green, Keith H Nuechterlein, James M Gold, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 3, 2009
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaChristine E Marx, Richard S E Keefe, Robert W Buchanan, et al.
The Journal of Clinical Psychiatry|June 13, 2012
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trialRichard S E Keefe, Sophia Vinogradov, Alice Medalia, et al.
Schizophrenia Research|March 25, 2023
Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disordersLusi Zhang, Paulo Lizano, Yanxun Xu, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 15, 2025
Beyond symptom improvement: transdiagnostic and disorder-specific ways to assess functional and quality of life outcomes across mental disorders in adultsChristoph U Correll, Samuele Cortese, Marco Solmi, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 10, 2021
Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disordersLusi Zhang, Scot Kristian Hill, Bin Guo, et al.
Archives of General Psychiatry|June 10, 2010
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosisLarry J Seidman, Anthony J Giuliano, Eric C Meyer, et al.
Archives of General Psychiatry|June 6, 2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialRichard S E Keefe, Robert M Bilder, Sonia M Davis, et al.
Nature Medicine|April 2, 2020
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedoniaAndrew D Krystal, Diego A Pizzagalli, Moria Smoski, et al.
Pageof 26